IMbrave050: Phase 3 study of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation

被引：0

作者：

Trojan, J. ^{[1
]}

Chow, P. ^{[2
,3
]}

Chen, M. ^{[4
]}

Cheng, A-L ^{[5
,6
]}

Kaseb, A. ^{[7
]}

Kudo, M. ^{[8
]}

Lee, H. C. ^{[9
]}

Yopp, A. ^{[10
]}

Zhou, J. ^{[11
]}

Wang, L. ^{[12
]}

Wen, X. ^{[13
]}

Heo, J. ^{[14
,15
]}

Tak, W-Y ^{[16
]}

Nakamura, S. ^{[17
]}

Numata, K. ^{[18
]}

Uguen, T. ^{[19
]}

Hsieh, D. ^{[10
]}

Cha, E. ^{[20
]}

Hack, S. P. ^{[20
]}

Lian, Q. ^{[20
]}

Spahn, J. ^{[20
]}

Wu, C. ^{[21
]}

Qin, S. ^{[22
]}

机构：

[1] Univ Klinikum Frankfurt, Frankfurt, Germany

[2] Natl Canc Ctr Singapore, Singapur, Singapore

[3] Duke NUS Med Sch, Singapur, Singapore

[4] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Guangdong, Peoples R China

[5] Natl Taiwan Univ, Ctr Canc, Taipei, Taiwan

[6] Natl Taiwan Univ Hosp, Taipei, Taiwan

[7] MD Anderson Canc Ctr, Houston, TX USA

[8] Kindai Univ, Osaka, Japan

[9] Univ Ulsan, Asan Med Ctr, Seoul, South Korea

[10] UT Southwestern Med Ctr, Dallas, TX USA

[11] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China

[12] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China

[13] 1st Hosp Jilin Univ, Jilin, Jilin, Peoples R China

[14] Pusan Natl Univ, Coll Med, Busan, South Korea

[15] Pusan Natl Univ Hosp, Biomed Res Inst, Busan, South Korea

[16] Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Daegu, South Korea

[17] Himeji Red Cross Hosp, Himeji, Hyogo, Japan

[18] Yokohama City Univ, Med Ctr, Yokohama, Kanagawa, Japan

[19] Hosp Pontchaillou, Rennes, France

[20] Genentech Inc, San Francisco, CA USA

[21] Roche Holding Ltd, Shanghai, Peoples R China

[22] Nanjing Univ Chinese Med, Jinling Hosp, Nanjing, Peoples R China

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P687

引用

页码：239 / 239

页数：1

共 50 条

[31] A phase III study of atezolizumab (atezo) vs placebo as adjuvant therapy in renal cell carcinoma (RCC) patients (pts) at high risk of recurrence following resection (IMmotion010)
Uzzo, Robert
Bex, Axel
Rini, Brian I.
Albiges, Laurence
Suarez, Cristina
Donaldson, Frank
Asakawa, Takashi
Schiff, Christina
Pal, Sumanta K.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[32] Preliminary results of ALTER-H006: A phase II study of TQB2450 plus anlotinib as adjuvant therapy in hepatocellular carcinoma (HCC) with high risk of recurrence after radical resection
Mao, Xianhai
Duan, Xiaohui
Wu, Dongde
Zhou, Cuncai
Tian, Yifeng
Shen, Jian
Xu, Guohui
Lai, Jianlin
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 494 - 494
[33] Albumin-Bilirubin Grade Analyses of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study
Kudo, Masatoshi
Finn, Richard S.
Cheng, Ann-Lii
Zhu, Andrew X.
Ducreux, Michel
Galle, Peter R.
Sakamoto, Naoya
Kato, Naoya
Nakano, Michitaka
Jia, Jing
Vogel, Arndt
LIVER CANCER, 2023, 12 (05) : 479 - 493
[34] Update results of ALTER-H006: A phase II study of TQB2450 plus anlotinib as adjuvant therapy in hepatocellular carcinoma (HCC) with high risk of recurrence after surgical resection
Mao, X.
Duan, X.
Wu, D.
Zhou, C.
Tian, Y.
Shen, J.
Xu, G.
Bai, Y.
ANNALS OF ONCOLOGY, 2024, 35 : S658 - S658
[35] Letter regarding "Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study"
Hatanaka, Takeshi
Hiraoka, Atsushi
Tada, Toshifumi
Kakizaki, Satoru
LIVER CANCER, 2024, 13 (06) : 669 - 670
[36] IMbrave150: updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC)
Finn, Richard S.
Qin, Shukui
Ikeda, Masafumi
Galle, Peter R.
Ducreux, Michel
Mertens, Joachim
Kim, Tae-You
Kudo, Masatoshi
Lim, Ho Yeong
Breder, Valeriy
Merle, Philippe
Kaseb, Ahmed
Li, Daneng
Feng, Yin-Hsun
Verret, Wendy
Nicholas, Alan
Li, Lindong
Ma, Ning
Zhu, Andrew X.
Cheng, Ann-Lii
SWISS MEDICAL WEEKLY, 2021, 151 : 25 - 26
[37] Re: Adjuvant Atezolizumab Versus Placebo for Patients with Renal Cell Carcinoma at Increased Risk of Recurrence Following Resection (IMmotion010): A Multicentre, Randomised, Double-blind, Phase 3 Trial
Wu, Zhenjie
Wang, Linhui
Pandolfo, Savio D.
Autorino, Riccardo
EUROPEAN UROLOGY, 2023, 83 (03) : 297 - 298
[38] IMbrave150: Updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC).
Finn, Richard S.
Qin, Shukui
Ikeda, Masafumi
Galle, Peter R.
Ducreux, Michel
Kim, Tae-You
Kudo, Masatoshi
Lim, Ho Yeong
Breder, Valeriy
Merle, Philippe
Kaseb, Ahmed
Li, Daneng
Feng, Yin-Hsun
Verret, Wendy
Nicholas, Alan
Li, Lindong
Ma, Ning
Zhu, Andrew X.
Cheng, Ann-Lii
CANCER RESEARCH, 2021, 81 (13)
[39] Reply to the Letter Regarding "Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study"
Kudo, Masatoshi
Tsuchiya, Kaoru
Yamashita, Tatsuya
Koga, Hironori
Nakagawa, Yuki
Ikeda, Masafumi
LIVER CANCER, 2024, 13 (06) : 671 - 673
[40] IMbrave150: Exploratory analysis to examine the association between bevacizumab (bev) ever being skipped and bev never being skipped in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) plus bev in a global phase 3 study.
Kudo, Masatoshi
Tsuchiya, Kaoru
Shao, Yu Yun
Finn, Richard S.
Galle, Peter R.
Ducreux, Michel
Cheng, Ann-Lii
Yamashita, Tatsuya
Koga, Hironori
Aoki, Kenichi
Yamada, Kyoko
Asakawa, Takashi
Nakagawa, Yuki
Ikeda, Masafumi
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 538 - 538

← 1 2 3 4 5 →